Biogen verzeichnet rasanten Anstieg - 500 Beiträge pro Seite

[spirou]

Hallo zusammen,
in den letzten zwei Tagen kann die Aktie der Biogen AG
rasante Zuwächse verzeichnen. Gestern 12 % und heute wieder
rund 11%. Den Grund wird wahrscheinlich folgende Nachricht
sein:

BIOGEN AND CV THERAPEUTICS SAY ADENOSINE A1 ANTAGONIST IS SUCCESSFUL IN A PHASE II
TRIAL

Cambridge, MA, and Palo Alto, CA (February 17, 2000) - Biogen, Inc. (NASDAQ/BGEN) and CV Therapeutics, Inc.
(NASDAQ/CVTX) today announced that Biogen`s adenosine A1 antagonist/CVT-124 compound successfully
completed a Phase II trial in patients with moderate-to-severe Congestive Heart Failure (CHF). Biogen said it would
continue studies with its lead backup molecule.

Jim Vincent, Biogen`s Chairman and Chief Executive Officer, said, "This Phase II trial validates the potential of this
adenosine pathway in the cardio-renal syndrome that makes CHF such a deadly disease. We achieved statistical
significance on key clinical endpoints and are very pleased with what we have learned about this pathway in our
studies during the past three years. With this extensive experience, we believe we can make significant progress with
this program as we move it through the clinic."

Adenosine A1 antagonist/CVT-124 is a highly selective small molecule adenosine A1 receptor antagonist that targets
receptors in the kidney that are clinically relevant for the treatment of CHF. The Phase II trial was a randomized,
double-blinded, placebo-controlled, dose-ranging study of the molecule in moderate-to-severe heart failure patients
used in conjunction with standard therapies.

Biogen said it will make a milestone payment to CV Therapeutics, from which it licensed the program.

In addition to historical information, this press release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Reference is made in particular to
statements regarding continuation of clinical studies of a new adenosine A1 antagonist molecule and the expected
progress of such studies. These statements are based on the Companies` current beliefs and expectations as to such
future outcomes. Factors which could cause actual results to differ materially from the Companies` current
expectations include the risk that the new molecule to be studied will not yield the same clinical results as the molecule
that was the subject of the completed Phase II trial or that problems or delays may arise during preparations for future
clinical trials or in the conduct of such trials or that problems may arise with respect to toxicology, formulation of
manufacturing of the new molecule, as well as the other risks and uncertainties described from time to time in the
Companies` periodic reports filed with the Securities and Exchange Commission. Drug development involves a high
degree of risk. Success in early stage clinical trials does not ensure that later stage or larger scale clinical trials will be
successful.

Biogen, Inc., winner of the 1998 U.S. National of Technology, is a biopharmaceutical company principally engaged in
discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company`s revenues are generated from worldwide sales of AVONEX® (Interferon beta-1a) for treatment of
relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including
alpha interferon and hepatitis B vaccines and diagnostic products. Biogen`s research and development activities are
focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in
developmental biology and gene therapy. For copies of press releases and additional information about the
Company, please consult Biogen`s Homepage on the World Wide Web at http://www.biogen.com.

CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a biopharmaceutical company focused on applying
molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the
treatment of cardiovascular diseases. CVT is currently conducting clinical studies for two of its products. Ranolazine,
the first in a new class of drugs known as partial fatty acid oxidation (pFOX) inhibitors for the potential treatment of
angina, is in Phase III clinical trials. CVT-510, for the potential treatment of atrial arrhythmias, is in Phase II clinical
trials. For more information, please visit CV Therapeutics` web site at www.cvt.com.

Schönen Tag noch

spirou

[megaschotte]

Hallo spirou,

danke für Deine Info. Biogen macht mir seit dem Kauf Mitte Dezember letzten Jahres nur Freude. Im Gegensatz zu Morphosys, wo man noch Grundlagenforschung betreibt, ist man bei Biogen mit der Entwicklung eines neuen Herz-Medikamentes bereits in der klinischen Erprobung; die Marktreife in erreichbarer Nähe!

Die Aktie birst vor Power; Greespan wird ihr nichts anhaben können.
Nächstes Kursziel 160 Euro. Nicht verkaufen!!!

[spirou]

Hallo megaschotte,
ich finde Biogen braucht jedes vernünftige Depot einfach, da
Biogen schon eine gewisse größe aufweisen kann und dadurch auch
Flops (die Biogen wahrscheinlich sowieso nie haben wird) verkraften
kann. Der Flops eines Medikamentes von British Biotech
in der Testphase brach dem Aktienkurs das Genick und so mußten die
Aktionäre Abschläge von 50 % hinnehmen. Biogen ist einfach genial und
wird auch nach der Standard and Poors Aufnahme vermehrt von Fonds-
manager gekauft werden. Auch Avonex wird weiterhin gute Umsatz und
Gewinnzahlen aufweisen können, so daß ein Aktienkurs von rund 200 Euro
in den nächsten 6 Monaten meiner Meinung nach sehr wahrscheinlich
ist. Am Freitag haben wir ja schon 125 $ in Amerika gesehen, jedoch
konnte das Niveau nicht gehalten werden, aber es wurde klar wohin
der nächste Weg geht, nämlich Richtung Norden.

Schönen Tag noch

spirou

[spirou]

Hallo zusammen,
ich habe noch eine Empfehlung zu Biogen gefunden. Die Empfehlung
ist zwar schon recht alt, jedoch gibt sie sehr gut die wichtigsten
Argumente, die für Biogen sprechen, wieder.

26.01.2000
Biogen kaufen
Hornblower Fischer



Die Analysten von Hornblower Fischer raten dem Anleger derzeit zu einem
Engagement in Aktien des US-Unternehmens Biogen (866822).

Biogen sei eine der Branchengrößen im Biotechnologiesektor. Bereits 1996 habe
Biogen mit Avonex, einem Mittel gegen Multiple Sklerose (MS) sein erstes
Medikament auf den Markt bringen können. Inzwischen seien mit Diagnostika
und Impfstoffen gegen Hepatitis B und C, die in Kooperation mit führenden
Pharmaunternehmen vertrieben würden weitere Mittel hinzugekommen. In der gut
diversifizierten Produktpipeline von Biogen würden sich einige Medikamente
befinden, die kurz vor Abschluss ihrer Testphase stünden und deren
Markteinführung somit bevorstehe. Gestern sei nachbörslich die Nachricht
gekommen, dass Biogen aus dem S&P Midcap400 Index in den S&P 500
aufsteigen werde. Die Analysten gehen davon aus, dass Biogen von dieser
Änderung stark profitieren werde. Einen Grund sehen die Experten in der nun
folgenden Umstrukturierung von Investmentfonds. Außerdem sollte die derzeitige
Fokussierung des Marktes auf Biotechnologiewerte für eine besonders positive
Aufnahme dieser Meldung sorgen.

Die Experten raten daher Biogen zu kaufen.

Quelle: aktiencheck

Schönen Tag noch

spirou

[MogelTom]

...und was ist heute los?? Weiß jemand was?

[spirou]

Heute ist wohl nichts los, oder?
Haben die Amis einen Feiertag heute?

Zumindest noch einen schönen Tag

spirou

[spirou]

Hallo zusammen,
langsam kommt wieder Bewegung in diesen Wert. Biogen nimmt wieder Kurs
auf 125 Euro und wird sie die nächsten Tage auch durchbrechen.
Auch gibt es wieder neue News, jedoch sind sie nicht so spektakulär,
um auf den Aktienkurs einzuwirken





BIOGEN NAMES JOHN MCCOY, Ph.D., DIRECTOR, MOLECULAR TECHNOLOGIES

Cambridge, MA (February 24, 2000) - Biogen (NASDAQ/BGEN) today announced the appointment of John McCoy,
Ph.D., to the position of Director, Molecular Technologies. Dr. McCoy reports to Michael Gilman, Ph.D., Research
Director of Molecular Biology.

Dr. McCoy joins Biogen after 16 years at Genetics Institute Inc., where he was Senior Director of Molecular Biology
and Gene Expression, with responsibilities in the areas of genomics and functional genomics. Prior to that, Dr.
McCoy worked for three years with Nobel Laureate H. Gobind Khorana at the Massachusetts Institute of Technology.
Dr. McCoy earned his doctorate in biochemistry in 1980 from the University of Liverpool, UK.

Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally
engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company`s revenues are generated from worldwide sales of AVONEX® (Interferon beta-1a) for
treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen`s research and development
activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular
diseases and in developmental biology and gene therapy.

back to top

BIOGEN ANNOUNCES NEW EXECUTIVE ASSIGNMENTS IN ITS INTERNATIONAL OPERATIONS

Cambridge, MA (February 24, 2000) -- Biogen, Inc. (NASDAQ/BGEN) today announced several new assignments in
its International Group.

The following individuals report directly to Mark Leuchtenberger, Vice President, International, and are based at the
Company`s international headquarters in Paris:

David Allsop has been appointed International Marketing Director with responsibility for AVONEXÒ (Interferon
beta-1a), Biogen`s flagship product for the treatment of relapsing forms of multiple sclerosis. Prior to this assignment,
Mr. Allsop served as Biogen`s Country Manager, U.K. and Ireland. Previously, he worked for Janssen, where he held a
variety of marketing and sales positions.

Philippe Chanut has been appointed Director, Southern Europe. Prior to joining Biogen in 1999, Mr. Chanut served
as Marketing and Sales Director at Glaxo Wellcome France. Previously, he worked for the French Ministry of Industry
and Schering-Plough, in both France and the U.S.

The following individuals report directly to James Kirkness, Director of Northern Europe and Distributors:

Bill Anderson has been appointed Country Manager, U.K. and Ireland. Mr. Anderson joined Biogen in 1997 as a
Senior Financial Analyst. Previously, he managed the marketing effort for a digital projector venture in California and
conducted market research and acquisition and divestiture activity for a division of Raychem Corporation. Earlier in
his career, he worked for four years in Belgium, the Netherlands, and Germany in operations management roles. He
works from the Company`s U.K. office.

Biogen Announces New Executive Assignments in Its International Operations

Henk-Peter Oonk has been appointed Country Manager, Benelux. Until recently, he served as Biogen`s International
Marketing Manager. Before joining Biogen, Mr. Oonk held a variety of sales and marketing positions at
Rhone-Poulenc-Rorer, Yamanouchi Europe, and Hoechst Marion Roussel. He works from the Company`s office in
The Netherlands.

Karen Lykke Sørensen has been appointed Head of the Nordic Region. Ms. Sørensen joined Biogen in 1999 to
manage operations in Denmark, Norway, Sweden, and Finland. Previously, she worked at Dako A/S as Country
Manager for Denmark and Norway, with additional responsibility for business development. Ms. Sørensen works from
the Company`s office in Denmark.

Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally
engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company`s revenues are generated from worldwide sales of AVONEX® (Interferon beta-1a) for
treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen`s research and development
activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular
diseases and in developmental biology and gene therapy.

back to top

BIOGEN NAMES NADINE COHEN, Ph.D., DIRECTOR OF REGULATORY AFFAIRS

Cambridge, MA (February 24, 2000) - Biogen (NASDAQ/BGEN) today announced the appointment of Nadine
Cohen, Ph.D., to the position of Director, Regulatory Affairs. Dr. Cohen reports to Sylvie L. Grégoire, Pharm.D., Vice
President, Regulatory Affairs.

Dr. Cohen joined Biogen from the Massachusetts Biologics Laboratories, where she was Senior Director of Quality
Control and Technical Services. Prior to that, she worked at Alpha Beta Technology, Inc., as Vice President of
Regulatory Affairs and Quality. Dr. Cohen earned a Ph.D. in Biochemistry from the University of Rochester.

Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally
engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company`s revenues are generated from worldwide sales of AVONEX® (Interferon beta-1a) for
treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen`s research and development
activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular
diseases and in developmental biology and gene therapy.

back to top

BIOGEN NAMES RAYMOND G. ARNER CHIEF COUNSEL, INTELLECTUAL PROPERTY

Cambridge, MA (February 24, 2000) - Biogen (NASDAQ/BGEN) today announced the appointment of Raymond G.
Arner to the position of Chief Counsel, Intellectual Property, and Associate General Counsel. Mr. Arner reports to
Thomas Bucknum, Vice President-General Counsel and Secretary.

Mr. Arner joined Biogen from Pharmacia & Upjohn, where he was Vice President, Global Intellectual Property, and
Associate General Counsel. Previously, he served as Associate General Counsel, Intellectual Property, at DuPont
Merck. Mr. Arner earned his B.S. in Pharmacy from the Temple University School of Pharmacy and his J.D. from
Temple University School of Law.

Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally
engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in
Cambridge, MA, the Company`s revenues are generated from worldwide sales of AVONEX® (Interferon beta-1a) for
treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products,
including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen`s research and development
activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular
diseases and in developmental biology and gene therapy.

[spirou]

Hallo zusammen,
also ich muß schon sagen, das Interesse an Biogen ist hier nicht
sehr groß. Warum? Machen sich hier einige in die Hosen, bloß weil
Biogen auf 107 Euro steht? ;-)kleiner Scherz.

Bringt mal ein paar Neuigkeiten.

Schönen Tag noch und genießt das super Wetter heute

spirou

[spirou]

Hallo zusammen,
schade, daß hier keine Diskussion zustande kommt, vielleicht
braucht man halt wirklich so gute Argumente wie: "10000% in einer
Stunde bei Aktie 1254, aber warum weiß ich auch nicht".

Neuerdings gibt es auch eine deutsche HP von Biogen, oder gibt es
die schon länger und ich habe sie bloß nie gesehen?
Natürlich kann man die HP über www.biogen.de erreichen, jedoch
ist die amerikanische HP umfangreicher unter www.biogen.com

Schönen Tag noch

spirou

[BBBio]

Keine Diskussion?
Na ja, sämtliche Biotech-Freaks konzentrieren sich gerade auf BB Biotech

Und dort ist Biogen ja auch drinnen!

[e4 sf6]

GERÜCHTEKÜCHE.....

Hallo Biogenisten ,was ist los mit euerm Superstar aus Cambridge ?
In diversen US Boards kursieren seit heute Gerüchte AVONEX stünde
im Verdacht KREBSERREGEND zu sein... Du lieber Joseph.. Hätte ich
Anteile ,ich würde der Sache auf den Grund gehen.
Passt auf auf eure Bgen`s....

Regards
Checkmate

[spirou]

Hallo zusammen,
da ist man nur zwei Tage nicht online und dann geht Biogen so
abkacken. Natürlich gleich geschaut nach den Gründen, und hier
sind sie:

(In March 8 LONDON story headlined "UK MS sufferers fear drug costs may lead to ban," please read in 8th para...while the
government decided not to subsidise Glaxo-Wellcome`s <GLXO.L> anti-flu drug Relenza...instead of...and Glaxo Wellcome`s
anti flu drug have had to be rationed -- makes clear Relenza is not being rationed. A corrected version follows) -

LONDON, March 8 (Reuters) - Britain`s multiple sclerosis (MS) sufferers said on Wednesday they were afraid that cost-
cutting measures may force a government ban on the only drug that reduces their syptoms and slows the disease`s progress.

"Those lucky enough to have the drug worry it will be withdrawn from them on grounds of affordability," said Peter Cardy, chief
executive of the MS Society of Great Britain and Northern Ireland.

"Many others wonder if they will ever get a proven and licensed drug which they see benefiting others."

The drug, which is based on a genetically modified beta interferon molecule, is not prescribed uniformly across Britain and the
MS society says the government must provide equal access to all MS sufferers.

A drug based on the beta interferon molecule is already produced by Biogen Inc. <BGEN.O> of the United States, Germany`s
Schering <SCHG.F> and Switzerland`s Ares-Serono <AREZ.S>, a spokesman for the MS Society told Reuters .

A poll carried out by the MS society showed that nine out of 10 UK MS specialist neurologists wanted to be able to prescribe
beta inteferon for their patients.

Britain`s National Health Service has been under the spotlight this year with a lack of funding causing bed shortages and
increasing queues for operations.

The cuts have also meant that certain drugs, including the impotence drug Viagra, made by Pfizer <PFE.N>, have been rationed
while the government decided not to subsidise Glaxo-Wellcome`s <GLXO.L> anti-flu drug Relenza until it proved its efficacy
and cost effectiveness to the National Institute of Clinical Excellence.

Wide variations in funding across the country mean that only three percent of MS patients receive beta interferon, compared
with about 14 percent in other parts of Europe and North America and 30 percent in Australia.

MS is an auto-immune disease in which the body`s immune system destroys a sheath which protects the nerve cells in the brain
and spinal cord, causing paralysis, pain and tremors.

The disease affects around one million people worldwide and 85,000 in Britain. There is no cure.

REUTERS



Also ich habe die News nur kurz durchgelesen, aber wenn ich richtig
liege, geht es nur darum, daß in GB das Medikament Avonex nicht mehr
per Rezept/mit Zuschüssen erhältlich ist. Oder??? Werde Artikel
noch genauer lesen, aber wenn dies der Grund für den Einbruch ist
kann ich nur sagen NACHKAUFEN, sollte sich jedoch herausstellen, daß
dieses Medikament krebseregend ist (was ich nicht bestätigen und
glauben kann) heißt das dann VERKAUFEN. Falls jemand weitere News
findest bitte posten.

Trotzdem noch einen schönen Abend

spirou, der etwas traurig ist

[spirou]

Hallo Leute,
also es bleibt bei der oben genannten Neuigkeit, die für den
Einbruch verantwortlich war. Jedoch denke ich, daß die Regierung
von GB hier keine Einsparungen vornehmen kann und wird, da diese
Medikamente die einzige Möglichkeit sind gegen MS vorzugehen, deshalb
war der Kursabschlag nur eine Überreaktion und wahrscheinlich vielen
noch einige stop loss bei 100 Euro und 90 Euro und so war der
Weg für Biogen nach unten frei. Ich überlege deshalb noch einmal
eine Position in Biogen aufzubauen, da mit rund 83 Dollar wir einen
Abschlag von 30 % vom All Time High haben.

Na denn noch einen schönen Abend

spirou

[e4 sf6]

Halo spirou,

Ich denke auch du hast schon recht,nur weiss ich nicht ob in der
news überhaupt Avonex gemeint ist. Schliesslich gibt es noch Intron-a
von Schering-Plough , Copaxone von Ares-serono (das im Verdacht steht
ein besseres Wirkungsprofil als Avonex zu erzielen) und Rebif von Teva.
In den US Boards ist der zukünftige "Cash-cow" Status von Avonex
stark umstritten eben wegen der aufkeimenden Konkurrenz. Mehr konnte ich
bis jetzt auch nicht in Erfahrung bringen. Chiau

[optimi]

Na hoffentlich habt ihr Recht und die Reaktion war übertrieben, ich bin seit 3 Monaten drinnen und falle jetzt ins Minus ab. Nach den letzten beiden Tagen geht mein Arsch auf Grundeis - so was bin ich, obwohl ich stark in den Biotechs veranlagt bin, nicht gewöhnt.
Optimi

[spirou]

Hallo zusammen,
also in Bezug auf den Kurseinbruch habe ich keine weiteren News
gefunden, jedoch andere interessante und gute Neuigkeiten, hier
sind ein paar Empfehulungen der letzten paar Tage für Biogen:

21.02.2000
Biogen Kursziel $145
Paine Webber



Die Analysten von Paine Webber haben am Wochenschluß die Aktie des
US-Biotechnologieunternehmens Biogen (WKN: 866822, BGEN) empfohlen.

Analystin Elise Wang sagte, daß sie das Kursziel von $105 auf $145 angehoben
habe. Gleichzeitig empfehle sie das Papier zum Kauf. Aufgrund der derzeit guten
Schlagzeilen für das Unternehmen, glaube man, daß das Momentum weiterhin in
der Aktie bleibe.

BGEN habe am Donnerstag bekanntgegeben, daß sich bei der Testphase II für
ein Medikament zur Behandlung von kongestiven Herzkrankheiten positive
Ergebnisse ergeben hätten. Die Ergebnisse hätten die Erwartungen des
Management übertroffen. Des weiteren dürfte der starke Verkauf des
Blockbusters Avonex weiter anhalten.

und da war doch noch was:


29.02.2000
Biogen chancenreich
Der Wachstumsinvestor



Die Experten von „Der Wachstumsinvestor“ sehen in der Biogen-Aktie (WKN
866822) ein chancenreiches Investment.

1996 habe Biogen mit Avonex ein erstes eigenes Medikament auf den Markt
gebracht. Das Multiple-Sklerose-Medikament sei ein echter Verkaufsschlager,
83.000 Menschen seien weltweit im vergangenen Jahr mit dem Medikament
behandelt worden. Mit Avonex habe man 621 Millionen Dollar umgesetzt – 55
Prozent mehr als im Vorjahr. Darüber hinaus vertreibe man verschiedene
Medikamente in Zusammenarbeit mit großen Pharmakonzernen wie Merck,
Smithkline Beecham oder Schering-Plough. Die derzeit noch starke
Abhängigkeit von Avonex sollte aber kein allzu großes Problem darstellen, so die
Experten. Mehr als zehn Präparate würden sich momentan in den Phasen II und
III der klinischen Forschung befinden.

Positiv sei außerdem die Tatsache, dass die Aktie durch die Aufnahme in den
S&P-500-Index zunehmend in den Fokus von Fondsmanagern rücke, so die
Experten.

und um jetzt auch noch die letzten Zweifler zu beruhigen:



10.03.2000
Biogen ein attraktives Investment
Wirtschaftswoche heute



Die „Wirtschaftswoche heute“ hält die Aktien des
US-Biotechnologieunternehmens Biogen (WKN: 866822, BGEN) für ein
aussichtsreiches Investment

Der amerikanische Biotechnologie-Pionier Biogen sei 1978 von fünf
Wissenschaftlern gegründet worden. Acht Jahre später habe das Unternehmen
vor dem Aus gestanden. Denn den hohen Aufwendungen für die Forschung
hätten kaum Einnahmen gegenübergestanden. Doch der Gesellschaft sei es
gerade noch gelungen, mit marktreifen Medikamenten den Konkurs zu
vermeiden.

Inzwischen gelte Biogen als Symbol für Wachstumsstärke. Allein im
vergangenen Jahr sei der Umsatz um 42 Prozent auf 794,4 Millionen Dollar
ausgeweitet worden. Für 2000 werde erstmals die Marke von einer Milliarde
Dollar ins Visier genommen.

Der Gewinn sei um 60 Prozent auf 220,5 Millionen Dollar gestiegen. Ähnlich wie
bei Scherings Betaferon erweise sich mit Avonex ein Medikament zur
Behandlung von Multipler Sklerose als Verkaufsschlager. Darauf entfielen etwa
80 Prozent der Erlöse.

Die Amerikaner hätten angekündigt, ihre Aktivitäten auf den deutschen Markt
auszuweiten. Börsianer halten es für möglich, daß Biogen nach Schering greife.
Für zusätzliche Phantasie sorge die bevorstehende Zulassung eines Präparats
zur Behandlung von Schuppen, betonen die Experten abschließend.

Also bei diesen niedrigen Kursen nachkaufen und freuen.


Schönen Tag noch

spirou

[Querkopf]

Na hoffentlich hast Du recht! Die Aktie notiert sehr nahe an meinem Stoppkurs!

[spirou]

Hallo Querkopf und der Rest,
klar Biogen wird schon wieder. Wenn dann kann den Aufwärtstrend nur
eine Korrektur an allen Börsen aufhalten. Weiter ist der heutige
Anstieg und die Stabilisierung des Kurses über der 100 Tagelinie,
was nur beruhigend ist. Also ich glaube, daß wir am Ende vom März noch
die 100 Euro wieder sehen und dann gehts es wieder auf die 125 Euro.

Den Neueinstieg kann ich nur empfehlen, da wir bis zum All Time High
50 % haben und das werden wir auf alle Fälle wieder sehen.

Schönen Abend noch

spirou

[spirou]

Hallo Leute,
da hätte ich doch glatt noch etwas vergessen:

KGV 00 01 bei 84 Euro

44 37

Tja wen das noch nicht überzeugt, der sollte dies noch lesen

Eigenkapitalquote von Biogen rund 78 %, da haben wir noch ein
bißchen Kohle für tolle Investments und Forschungen , also halten
und freuen.

spirou

[spirou]

Hallo Leute,
na also mit den Biotechwerten geht es wieder aufwärts und langsam
kapieren auch die letzten Leute, daß die Vereinbarungen von
Schröder und Clinton der Biotechbranche einen weiteren Auftrieb
bereiten und ihr nicht schaden, außerdem hatte dieses Thema ja nie
etwas mit Biogen zu tun.

In diesem Sinne noch einen schönen Tag

spirou

[spirou]

Hallo Leute,
wenn sich nie jemand zu Wort meldet, muß ich halt alleine
weitermachen, um euch mit den neuersten Infos um Biogen zu
versorgen.


16.03.2000
Biogen kaufen
Der Aktionärsbrief



Die Experten von „der aktionärsbrief“ empfehlen die Biogen-Aktie (WKN 866822)
zum Kauf.

In der seit März anhaltenden Schwäche der US-Biotechnologie hätten sich auch
die vermeintlichen Standardwerte nicht behaupten können. Der Kurseinbruch von
über 30 % solle jedoch als Chance zu einem billigen Einstieg gewertet werden.
Biogen sei eine der wenigen Gesellschaften der Branche, die bereits schwarze
Zahlen schreiben. Das nach eigenen Angaben älteste noch unabhängige
Biotechnologieunternehmen der Welt habe seinen Schwerpunkt in der Forschung
für Mittel zur Behandlung von Multiple Sklerose und zur Heilung von Infektions-,
Nieren- und Herzkrankheiten. Mit dem Hauptpräparat Avonex seien im
vergangenen Jahr 620 Mio. $ erlöst worden, mit der gesamten Produktpalette ein
Gewinn von 220 Mio. $ oder 1,40 $ je Aktie verdient worden. Im laufenden Jahr
rechnen die Experten mit einem Ergebnis trotz heftiger Konkurrenz von
Scherings Betaferon von 1,90 $ je Aktie.

Die jüngst bekanntgegebene Einstellung der Versuche mit dem Medikament
Antova, die ursächlich für den Preisverfall gewesen sei, sei im Kurs mittlerweile
eingepreist, so der aktionärsbrief.


Genau mein Reden.

Schönen Tag noch


spirou

[defcon]

Hi,

erst mal Dank an Alle für die guten Infos,
habe heute Biogen gekauft. Gibt es irgendwelche neue Meldungen?
Wieso ist Biogen trotz der guten Nasdaq gefallen? Naja,
ich denke das werden wohl noch die Nachwehen von Clinton
und Schröder sein. Prudential Security hat heute nochmals betont,
daß die Biotechbranche von der Vereinbarung (Offenlegung von
Ergebnissen) profitieren werde, da die Entwicklung nun noch
stärker vorangetrieben werde. (Telebörse von NTV um 22:15).
Ich denke wenn der Letzte begriffen hat, daß die Vereinbarung
vorteilhaft ist und die ganzen Abschläge bei den Aktien nicht
gerechtfertigt waren, dann gehts wieder Richtung alte Höhen.
Vor allem Biogen als etablierte Firma sollte doch hier enorm
profitieren können, da Sie auch fundamental "billig" sind (KGV 2001/37).

Auf steigende Kurse

Defcon

[spirou]

Hallo defcon,
ich wünsche dir viel Spaß und freude an Biogen.

spirou

[spirou]

Ich bin es noch einmal.
Hier habe ich noch was über Biogen gefunden, jedoch noch nicht ausgewertet,
da ich euch natürlich diese News nicht vorenthalten möchte:


Arbitration Ruling Denies Biogen`s Claims Against Schering-Plough on Sales of REBETRON

CAMBRIDGE, Mass., March 22 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) today announced that an arbitration panel
has ruled that Schering-Plough`s REBETRON is not a combination product as defined under a 1979 agreement between the
two companies. Biogen said it would suffer no financial impact based on the arbitration panel`s decision since Schering-Plough is
presently paying royalties on the INTRON A component and the decision will have no effect on those royalties. ( Photo:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )

Biogen initiated arbitration proceedings in December 1998, claiming that Schering-Plough had breached the 1979 agreement by
underpaying royalties to Biogen on sales of REBETRON. Under the 1979 agreement, Biogen licensed to Schering-Plough rights
under Biogen`s alpha interferon patents, and receives royalties from Schering-Plough based on sales of Schering-Plough`s
INTRON A (Interferon alfa-2b, recombinant) injection product and REBETRON, which is a combination pack containing
INTRON A and REBETOL (ribavirin, USP) capsules. The arbitration panel rejected Biogen`s claim that REBETRON is a
combination product and that royalty payments should be based on the higher rate for combination products called for under the
1979 agreement, and not on the INTRON A component alone.

Jim Vincent, Biogen`s Chairman and Chief Executive Officer, said, "We are disappointed by the arbitrators` ruling, and do not
agree with their conclusion that REBETRON is not a "combination product" under our agreement. However, there is no financial
loss to Biogen and we continue to benefit from the rapid growth in sales of REBETRON in the form of royalties on INTRON
A."

In addition to historical information, this press release contains forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Reference is made in particular to forward- looking statements regarding the meaning
and potential impact of the results of the arbitration panel`s decision and the Company`s expectations as to continuing benefit
from sales of REBETRON. These statements are based on the Company`s current beliefs and expectations as to such future
outcomes. Factors which could cause actual results to differ materially from the Company`s current expectations include the risk
that Schering-Plough`s sales of INTRON A and REBETRON might decrease in the future and the risk that patent-related issues
might affect royalty amounts.

Biogen, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in
discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the
Company`s revenues are generated from worldwide sales of AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms
of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis
B vaccines and diagnostic products. Biogen`s research and development activities are focused on novel products for multiple
sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy.


Schönen Tag noch

spirou

[spirou]

Hallo zusammen!
Ihr habt wahrscheinlich folgende Mail zwar schon erhalten, aber
zur Sicherheit poste ich sie noch zusätzlich:

Biogen verliert Schlichtungsfall

Biogen Inc. kommt heute unter Druck, nachdem es
einen Schlichtungsfall gegen Schering Plough Corp (NYSE:SGP) über die
Berechnung von Lizenzgebührzahlungen verloren hat. Bei dem Fall ging
es um den Verkauf des Hepatitis C Medikaments Rebetron.


Die Schlichtungs-Entscheidung besagt, dass Biogen nur Gebühren auf den
Verkauf von Intron A - eines von zwei Bestandteilen
von Rebetron – erheben darf. Irrelevant ist, ob Intron
A alleine verkauft wird oder als Teil des Rebetronpakets.


Biogen büßt derzeit bei einem Kurs von 76 1/4
US-Dollar 6,44% ein.


Tja weiter kann ich kein Statement abgeben, da ich die weiteren Folgen
nicht abschätzen kann, trotzdem noch schönen Abend

spirou

[thinkandtrade]

Lieber spirou,

Du scheinst ja ein kleiner Alleinunterhalter zu sein. Das soll jetzt ein Ende haben:

Der verlorene Schlichtungsfall wird keine negativen Ausirkungen auf die Einnahmeprognosen haben, da die potentiellen Einnahmen bei gewonnener Schlichtung nicht mit eingeplant waren.

Weiteres später.

[Mebay]

ich habe heute biogen gekauft weil es zukunft hat

[Ruben]

man sollte sie Langfristig betrachten, dann ist Biogen ein Gewinn

[spirou]

Hallo thinkandtrade,
ich freue mich, daß du dich hier beteiligen möchtest, da das Interesse
wirklich nicht so groß an Biogen ist (gemäßen an den Beiträgen).

Dir Mebay wünsche ich noch viel Spaß mit Biogen.

Schönen Tag noch

spirou

[spirou]

Hier das letzte Posting von meiner Seite in diesem Thread, da der
Thread schon recht lange ist und durch das Einfügen des Jahresberichts
von Biogen erst recht den Thread sprengt.

Also hier der Jahresbericht von Biogen und viel Spaß beim studieren:


UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-K
(Mark One)

[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1999

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission file number: 0-12042

BIOGEN, INC.
(Exact name of Registrant as specified in its charter)

Massachusetts 04-3002117
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)



14 Cambridge Center, Cambridge, Massachusetts 02142
(Address of principal executive offices) (zip code)

Registrant`s telephone number, including area code: [phone]

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.01
par value
(Title of class)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes _X_ No ___

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will
not be contained, to the best of Registrant`s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

Aggregate market value of Common Stock held by nonaffiliates of the Registrant at March 16, 2000 (excludes shares held by
directors):
$12,913,220,996. Exclusion of shares held by any person should not be construed to indicate that such person possesses the
power, direct or indirect, to direct or cause the direction of management or policies of the Registrant, or that such person is
controlled by or under common control with the Registrant. Common Stock outstanding at March 16, 2000: 150,926,556
shares.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant`s definitive Proxy Statement for its 2000 Annual Meeting of Stockholders are incorporated by
reference into Part III of this Report, and portions of the Registrant`s 1999 Annual Report to Shareholders are incorporated by
reference into Parts II and IV of this Report.

2


PART I

ITEM 1 - BUSINESS

OVERVIEW

Biogen, Inc. ("Biogen" or the "Company") is a biopharmaceutical company principally engaged in the business of developing,
manufacturing and marketing drugs for human health care. Biogen, which was founded in 1978 and recently added by Standard
& Poor`s to the benchmark S&P 500 Index, currently derives revenues from sales of its AVONEX(R) (Interferon beta-1a)
product for the treatment of relapsing forms of multiple sclerosis and from royalties on worldwide sales by the Company`s
licensees of a number of products covered under patents controlled by the Company. Such products include certain forms of
alpha interferon, hepatitis B vaccines and hepatitis B diagnostic test kits, among others. The Company`s revenues from sales of
AVONEX(R) in 1999 were approximately $620.6 million, making AVONEX(R) the worldwide market leader among multiple
sclerosis therapies. The Company`s royalty revenues in 1999 were approximately $173.8 million.

Biogen continues to have an active development program related to AVONEX(R), and is conducting several important clinical
trials of the product. In 1999, Biogen completed a clinical study of AVONEX(R) in patients who had experienced only one
confirmed demyelinating event (multiple sclerosis-type exacerbation). The study showed a highly statistically significant beneficial
effect of AVONEX(R) in delaying the development of clinically definite multiple sclerosis. The study was stopped early following
positive results. The Company intends to file an application for a broadened prescribing label for AVONEX(R) with regulatory
agencies worldwide.

Biogen also continues to devote significant resources to its ongoing research and development efforts. The Company focuses its
efforts on areas where it has particular scientific strengths such as: multiple sclerosis, inflammatory diseases, cardiovascular
diseases, developmental biology and gene therapy. In 1999, the Company completed a Phase 2b clinical study of its
AMEVIVE(TM) (Human LFA-3/IgG1 fusion protein) product, also known as LFA3TIP, in patients with moderate to severe
chronic plaque psoriasis. Based on the encouraging Phase 2b data, the Company began a Phase 3 clinical trial in North
America, and is moving forward with planning for a Phase 3 clinical trial in Europe. Biogen anticipates beginning Phase 2 clinical
trials of AMEVIVE(TM) in a second indication during 2000. The Company also recently announced that it had successfully
completed an early-stage Phase 2 study of an adenosine A(1) antagonist small molecule product being studied as a treatment for
congestive heart failure. Additional studies using the lead back-up molecule for this pathway are planned. A third Biogen product
candidate in clinical trials experienced a set back in 1999. In November 1999, the Company announced that it had halted all
ongoing clinical trials of ANTOVA(TM) (Humanized anti-CD40 ligand monoclonal antibody), also known as humanized 5c8,
until it has completed a review of issues relating to adverse incidents involving thrombo-embolic events. Work to identify the
reasons for the adverse events is ongoing.

Biogen also has many earlier-stage research programs. These include: a program directed toward developing a novel inhibitor of
a particular immune response pathway as a potential therapy for several autoimmune diseases; a program focused on finding oral
small molecule drug candidates to inhibit the migration of white blood cells into tissue as a potential treatment for multiple
sclerosis and

2
3

certain chronic inflammatory diseases; a program in which the Company is exploring ways to treat certain central nervous system
disorders through use of proteins involved in inducing the formation and regeneration of tissue; and a program directed at
developing products based on human gene therapy technology. The Company is also exploring the use of functional genomics
technology to find novel therapeutics.

AVONEX(R) (INTERFERON BETA-1A)

Biogen currently markets and sells AVONEX(R) (Interferon beta-1a) for the treatment of relapsing forms of multiple sclerosis.
Multiple sclerosis is a progressive neurological disease in which the body loses the ability to transmit messages among nerve
cells, leading to a loss of muscle control, paralysis and, in some cases, death. Patients with active relapsing multiple sclerosis
experience an uneven pattern of disease progression characterized by periods of stability interrupted by flareups of the disease
after which the patient returns to a new baseline of functioning. AVONEX(R) is a recombinant form of a protein produced by
fibroblast cells in response to viral infection. AVONEX(R) has been shown in a pivotal clinical trial both to slow the
accumulation of disability and to reduce the frequency of exacerbations in patients with relapsing forms of multiple sclerosis.

Biogen began selling AVONEX(R) in the United States in 1996, and in the European Union ("EU") in 1997. AVONEX(R) is
on the market in over 50 countries, including Argentina, Australia, Brazil, Canada, Chile, Columbia, Cyprus, the Czech
Republic, the countries of the EU, Hungary, Israel, Mexico, Norway, Slovakia, South Africa, Switzerland, Turkey and the
United States.

In the United States, Canada and most of the major countries of the EU, Biogen uses its own sales force to market
AVONEX(R). In those countries, Biogen distributes AVONEX(R) principally through wholesale distributors of pharmaceutical
products, mail order, specialty distributors or shipping service providers. In other countries, Biogen sells AVONEX(R) to
distribution partners who are then responsible for most marketing and distribution activities. The Company has entered into
distribution agreements covering Australia, Eastern Europe, Greece, Israel, Italy, Japan, Latin America, the Middle East, New
Zealand, Portugal, South Africa, Spain and Turkey. Under most of these agreements, the distribution partners are responsible
for marketing and distributing AVONEX(R).

Biogen is currently conducting several clinical studies of AVONEX(R). These include: a dose comparison study, initiated in
1996, comparing the approved dosage of AVONEX(R) with a higher dose; an open-label follow-up study initiated in 1995 to
obtain long-term safety and antigenicity data; a clinical study of AVONEX(R) in patients with secondary progressive multiple
sclerosis, initiated in 1998; and a Phase 2 clinical study of AVONEX(R) in the treatment of idiopathic pulmonary fibrosis which
also commenced in 1998.

Biogen also recently completed a clinical study of AVONEX(R) in patients who had experienced only one confirmed
demyelinating event (multiple sclerosis-type exacerbation). The study, which was initiated in 1996, showed a highly statistically
significant beneficial effect of AVONEX(R) in delaying the development of clinically definite multiple sclerosis. Clinically definite
multiple sclerosis is identified by the presence of at least two demyelinating events, separated by time and location in the central
nervous system. The study was stopped early following positive results. The Company intends to file an application for a
broadened prescribing label for AVONEX(R) with regulatory agencies worldwide.

3
4

Biogen is also exploring new ways to improve the formulation and delivery of AVONEX(R). In February 1999, Biogen entered
into a collaborative agreement with Inhale Therapeutic Systems, Inc. under which the parties are working towards development
of a dry powder formulation of AVONEX(R) for pulmonary delivery using Inhale`s deep-lung delivery system. Biogen is also
continuing to work towards development of a pre-filled syringe formulation of AVONEX(R).

Revenues from sales of AVONEX(R) in 1999 were $620.6 million or approximately 78% of total revenues. Revenues from
sales of AVONEX(R) in 1998 and 1997 were $394.9 million and $240.0 million, respectively, or approximately 71% and 58%
of total revenues, respectively. Approximately 71% of AVONEX(R) sales in 1999, 77% of AVONEX(R) sales in 1998, and
92% of AVONEX(R) sales in 1997, were generated in the United States. Sales to three major wholesale distributors and a
specialty distributor in the United States accounted for 13%, 11%, 11% and 15%, respectively, of total revenues in 1999.

MAJOR RESEARCH AND DEVELOPMENT PROGRAMS

Biogen`s research is focused on biological systems and processes where its scientific expertise in molecular biology, cell biology,
immunology and protein chemistry can lead to a greater understanding of disease processes and, as a result, to the creation of
new pharmaceuticals. Biogen selects product candidates from its research programs to test in clinical trials, focusing its efforts on
those agents which it believes have the greatest potential competitive advantages and large commercial markets. Described
below are Biogen`s major research programs.

AMEVIVE(TM) (LFA3TIP)

Inflammation is the result of the body`s immune response to infection and injury. In many autoimmune diseases, the inflammation
process is directed inappropriately against the body`s own tissues, causing temporary or permanent damage. Biogen has focused
the efforts of its inflammation programs on developing drugs to inhibit specific cellular interactions critical to the inflammation
process. Central to inflammation is the activation of T-cells, specialized white blood cells which initiate and control the immune
response. One of the cellular pathways which is important for the activation of T-cells is the LFA-3/CD2 pathway.
AMEVIVE(TM) (LFA3TIP) is a recombinantly engineered protein designed to modulate immune responses by binding to the
CD2 receptor. Biogen is developing AMEVIVE(TM) as a treatment for certain autoimmune diseases. In 1999, the Company
completed a Phase 2b clinical study of AMEVIVE(TM) in patients with moderate to severe chronic plaque psoriasis. Based on
positive data from the Phase 2b study, the Company began a Phase 3 study in North America and is moving forward with
planning for a Phase 3 study in Europe. Psoriasis is a chronic autoimmune disease that is characterized by inflammation and
thickening of the skin. An estimated 500,000 psoriasis patients in the United States have a severe enough form of the disease to
need systemic therapies. Biogen anticipates beginning Phase 2 clinical trials of AMEVIVE(TM) in a second indication during
2000.

ADENOSINE A(1) ANTAGONISTS

In March 1997, Biogen entered into a research collaboration and license agreement with CV Therapeutics, Inc. ("CVT")
pursuant to which the Company obtained rights under CVT`s patents and know-how to develop and market molecules that act
as highly selective antagonists of the adenosine A(1)

4
5

receptor. The adenosine A(1) receptor is expressed principally in the heart, brain and kidney, and in the kidney mediates
vasoconstriction, renal function and reabsorption of fluids. Biogen is developing small molecule adenosine A(1) antagonists as a
treatment for congestive heart failure. Congestive heart failure is a chronic progressive disease that affects four to five million
people in the United States. Patients with the disease experience both a chronic course as well as acute episodes of heart failure
that usually require hospitalization. Reduction in kidney function and the formation of edema, or fluid retention, in lungs and
extremities are significant symptoms of chronic heart failure, leading to increased morbidity, hospitalization and death. In 1999,
Biogen successfully completed an early-stage Phase 2 study comparing CVT-124, a particular small molecule product, with
existing therapies in the acute treatment of congestive heart failure. Additional studies using the lead back-up molecule for this
pathway are planned.

ANTOVA(TM) (HUMANIZED 5C8)

The human immune system generates two types of responses: humoral (also known as antibody) responses and cell-mediated
responses. When CD40 ligand ("CD40L") on the surface of an activated T-cell binds to CD40 on the surface of a B-cell, the
production of antibodies is triggered. When CD40L on the surface of an activated T-cell binds to CD40 on the surface of a
variety of other cells, such as macrophages and dendritic cells, the cells become activated, triggering an inflammatory response.
The inhibition of the CD40-CD40L pathway offers a unique target for modulating both types of immune responses.

Biogen is developing ANTOVA(TM), a humanized monoclonal antibody that binds to CD40L, as a treatment for a variety of
autoimmune diseases and as a therapy for preventing organ and cellular transplant rejection. During 1999, the Company was
involved in an ongoing Phase 2 safety study of ANTOVA(TM) in patients with immune thrombocytopenic purpura, as well as
Phase 2 studies of ANTOVA(TM) in lupus nephritis, renal transplantation, pancreatic islet cell transplantation, Factor VIII
inhibitor syndrome and multiple sclerosis. In November 1999, the Company announced that it had halted all existing clinical trials
of ANTOVA(TM) until it has completed a review of issues relating to adverse incidents involving thrombo-embolic events.
Work to identify the reasons for the adverse events is ongoing.

LT-BETA RECEPTOR

The lymphotoxin-beta receptor ("LT-Beta Receptor") pathway is involved in controlling the maintenance of proper immune
interactions and the correct positioning of key cell types in the immune system. Both elements are crucial for the immune system
to function properly. The LT-Beta Receptor pathway serves as a novel access point to modulate autoimmune disease. Biogen is
developing its LT-Beta Receptor as a potential treatment for certain autoimmune diseases and expects to start Phase 1 safety
studies in 2001.

VLA-4 INHIBITORS

VLA-4 (Very Late Antigen-4) is a receptor that appears on the surface of white blood cells and binds to VCAM-1, a protein
found on the surface of vascular endothelial cells, as well as extracellular matrix proteins, fibronectin and osteopontin. The
VLA-4 pathway facilitates migration of white blood cells into tissue as part of the body`s normal response during inflammation.
This inflammatory response

5
6

can be severely damaging or even life threatening when it is directed against the body`s own tissue in autoimmune diseases and
may cause serious collateral injury in chronic immune inflammatory diseases such as asthma. Biogen scientists have developed
VLA-4-specific small molecule inhibitors designed to interrupt the cell adhesion activity of VLA-4 as a means of blocking the
inflammation process in a highly specific manner.

In December 1997, Biogen entered into a collaborative research, development and license agreement with Merck & Co., Inc.
("Merck") under which Biogen and Merck are collaborating on developing small molecule inhibitors of VLA-4. Under the
agreement with Merck, Biogen has rights to develop, market and sell small molecule inhibitors of VLA-4 for the treatment of
multiple sclerosis, kidney diseases and disorders, inflammatory bowel disease and most diseases with small patient populations.
Merck has rights to develop, market and sell small molecule inhibitors of VLA-4 in all other indications, including asthma. Early
in 1999, Merck completed a Phase 2a study in asthmatic patients using an aerosolized small molecule inhibitor of VLA-4,
known as BIO-1211. Merck subsequently determined that the results of the trial did not support continued development of that
particular compound. Collaborative efforts to identify a suitable oral small molecule inhibitor drug candidate continue at Merck
and Biogen.

HEDGEHOG PROTEINS

Hedgehog proteins are a class of novel human proteins that are responsible for inducing the formation or regeneration of tissue.
In 1996, the Company entered into a research collaboration and license agreement with Ontogeny, Inc. ("Ontogeny") for the
development of three specific "hedgehog" proteins. Under its agreement with Ontogeny, Biogen has access to exclusive
worldwide rights to develop therapeutics directly based on Ontogeny`s proprietary family of sonic, indian and desert hedgehogs
for most disease indications. In 1998, Biogen and Ontogeny extended the hedgehog research program and broadened the
collaboration to include gene therapy. The Company`s current focus is the study of the hedgehog proteins for the treatment of
certain central nervous system disorders.

GENE THERAPY

In 1995, the Company entered into a collaborative research agreement with Genovo, Inc. ("Genovo") for the development of
certain human gene therapy treatments. Under this agreement, Biogen received rights related to certain diseases of the liver and
lung. Genovo has also granted to Biogen rights under Genovo`s gene therapy technology for development of certain gene
therapy products in connection with the treatment of cancer.

OTHER RESEARCH PROGRAMS

As part of its further research efforts, Biogen is exploring the use of growth factors to prevent or treat the degeneration of organs
following damage. The Company is also investigating new ways to modify immune responses more specifically in order to treat
diseases of the immune system. In addition, through its collaborations with CuraGen Corporation, Incyte Pharmaceuticals, Inc.
and Genetica Incorporated, Biogen is exploring the use of functional genomics technology to find novel therapeutics.

6
7

RESEARCH AND DEVELOPMENT COSTS

For the years ended December 31, 1999, 1998 and 1997, Biogen`s research and development costs were approximately
$221.2 million, $177.2 million and $145.5 million, respectively.

RISKS ASSOCIATED WITH DRUG DEVELOPMENT AND COMMERCIALIZATION

Certain of the statements set forth above regarding the Company`s research and development programs, such as statements
regarding the anticipated commencement of clinical trials of drugs in development, are forward-looking, and are based upon the
Company`s current belief as to the outcome and timing of such future events. These events are subject to a number of factors
and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements.
Many important factors affect the Company`s ability to successfully develop and commercialize drugs, including the need to
demonstrate the safety and efficacy of drug candidates at each stage of the clinical trial process, to overcome technical hurdles
that may arise, to meet applicable regulatory standards, to receive required regulatory approvals, to be capable of producing
drug candidates in commercial quantities at reasonable costs, to obtain and maintain all necessary patents or licenses, to
compete successfully against other products, and to market products successfully. There can be no assurance that any of the
products described in this section or resulting from Biogen`s research and development programs will be successfully developed,
prove to be safe and efficacious at each stage of clinical trials, meet applicable regulatory standards, be capable of being
produced in commercial quantities at reasonable costs, be successfully marketed or successfully meet challenges from
competitive products.

For a detailed discussion of the risks associated with the Company`s drug development and commercialization program, see the
Company`s 1999 Annual Report to Shareholders --- "Management`s Discussion and Analysis of Financial Condition and Results
of Operations --- Outlook," which is incorporated herein by reference under Item 7 hereof.

PRINCIPAL PRODUCTS BEING MARKETED OR DEVELOPED BY BIOGEN`S LICENSEES

ALPHA INTERFERON

Alpha interferon is a naturally occurring protein produced by normal white blood cells. Biogen has been granted patents covering
the production of alpha interferon through recombinant DNA techniques. See "Patents and Other Proprietary Rights." Biogen`s
worldwide licensee for recombinant alpha interferon, Schering-Plough Corporation ("Schering-Plough"), first began commercial
sales of its Intron(R) A brand of alpha interferon in the United States in 1986 for hairy-cell leukemia. Schering-Plough now sells
Intron(R) A worldwide for as many as 16 indications. The United States Food and Drug Administration (the "FDA") has
approved Intron(R) A for the treatment of chronic hepatitis B and hepatitis C, hairy-cell leukemia, AIDS-related Kaposi`s
sarcoma, condylomata acuminata, for injection as an adjuvant treatment to surgery in patients at high risk for systemic recurrence
of malignant melanoma, and for use in conjunction with anthracycline-containing combination chemotherapy for the initial
treatment of patients with clinically aggressive non-Hodgkin`s lymphoma.

In late 1998, Biogen filed for arbitration against Schering-Plough in a dispute over the amount of royalties payable to Biogen on
sales of REBETRON(R), a combination product containing the Intron(R) A injection product and REBETOL(R) (ribavirin,
USP capsules). Schering-Plough sells REBETRON(R) in the United States as a treatment for

7
8

chronic hepatitis C. A hearing in connection with the arbitration was conducted in January 2000. In March 2000, the arbitration
panel found in favor of Schering-Plough, and rejected Biogen`s claim that royalty payments should be based on the higher rate
for combination products called for under the 1979 agreement between the parties, and not on the Intron(R) A component
alone. Biogen does not expect to suffer any financial impact as a result of the arbitration panel`s decision since Schering-Plough
is presently paying royalties only on the Intron(R) A component, and the decision will have no effect on those royalties.

Royalties from Schering-Plough on sales of Intron(R)A accounted for approximately 13%, 16% and 19% of Biogen`s revenues
in 1999, 1998 and 1997, respectively.

For a discussion of the length of Schering-Plough`s royalty obligation to Biogen on sales of alpha interferon products, see
"Patents and Other Proprietary Rights - Recombinant Alpha Interferon."

HEPATITIS B VACCINES AND DIAGNOSTICS

Hepatitis B is a blood-borne disease which causes a serious infection of the liver and substantially increases the risk of liver
cancer. More than 250 million people worldwide have chronic hepatitis B virus infections. Biogen holds several important
patents related to hepatitis B antigens produced by genetic engineering techniques. See "Patents and Other Proprietary Rights -
Recombinant Hepatitis B Antigens." These antigens are used in recombinant hepatitis B vaccines and in diagnostic test kits used
to detect hepatitis B infection.

Hepatitis B Vaccines

Approximately 100 countries around the world, including the United States, have added the vaccination against hepatitis B to
their routine immunization programs for all children. The United States Centers for Disease Control and the American Academy
of Pediatrics have also recommended universal immunization of ten-year-old children and at-risk adolescents. The United States
Occupational Safety and Health Administration has recommended that all persons with an occupational exposure to blood and
other infectious material receive the hepatitis B vaccine.

SmithKline Beecham Biologicals s.a. ("SmithKline") and Merck are the two major worldwide marketers of hepatitis B vaccines.
Biogen has licensed to SmithKline exclusive rights under Biogen`s hepatitis B patents to market hepatitis B vaccines in the major
countries of the world, excluding Japan. SmithKline currently pays Biogen royalties based on sales of SmithKline`s vaccine in the
United States and in over 15 other countries. In 1990, SmithKline and Biogen entered into a sublicense arrangement with Merck
under which Biogen currently receives royalties. Biogen has also licensed rights relating to hepatitis B vaccines under its hepatitis
B patents to Merck and The Green Cross Corporation on a non-exclusive basis in Japan. Royalties from SmithKline and Merck
together accounted for approximately 6%, 9% and 14% of Biogen`s revenues in 1999, 1998 and 1997, respectively.

Hepatitis B Diagnostics

Biogen has licensed its proprietary hepatitis B rights, on an antigen-by-antigen and nonexclusive basis, to diagnostic kit
manufacturers. Biogen currently has hepatitis B license or license and supply agreements for diagnostic use with more than 15
companies, including Abbott Laboratories, the major worldwide marketer of hepatitis B diagnostic kits, Ortho-Clinical
Diagnostics, Organon Teknika B.V. and Roche Diagnostic Systems, Inc.

8
9

For a discussion of the length of the royalty obligation of SmithKline and Merck on sales of hepatitis B vaccines and the
obligation of Biogen`s other licensees on sales of hepatitis B-related diagnostic products, see "Patents and Other Proprietary
Rights - Recombinant Hepatitis B Antigens."

[spirou]

Nachdem ich nicht den ganzen Jahresbericht posten kann, gibt
es halt die adresse:

http://www.nasdaq.com/asp/quotes_news.asp?symbol=BGEN%60&sel…

einfach kopieren und einfügen

tschuldigung, daß ich keine links "machen kann"



spirou

[spirou]

In dieser heißen Phase rate ich von einem Neueinstieg noch momentan
ab, bis sich der Markt wieder beruhigt hat. Den Investierten kann ich
nur raten nicht den Mut verlieren, da Biogen wirklich ein klasse Unternehmen
mit Zukunft ist und deshalb man nach dieser Endzeitstimmung wieder
bessere Tage sehen wird.

spirou

[local hero 3]

Hi spirou,

ich bin seit kurzem ein grosser fan von der (CH-)Ares-Serono. Im Jahresbericht der Ares-Serono steht, dass es erhebliche Lizenzeinnahmen von Biogen W. Avonex bezieht.

Meine Frage: Wer hat Avonex entwickelt und wie partizipiert Ares-serono eigentlich an den verschiedenen Weiterentwicklungen an diesem Wirkstoff (Medikament)?

thanks in advance

[spirou]

Hallo local hero 3,
ich bin ebenfalls ein riesen Fan von ares-serono (siehe Thread von
mir) und es ist auch richtig, daß ares-serono Linzenzeinnahmen von
Biogen, Amgen und noch weiteren Biotechfirmen, jedoch weiß ich auch
nicht mehr. Jedoch werde ich mich mal schlau machen und hier im
Thread von Biogen und ares-serono das Ergebnis posten.

Schönen Tag noch

spirou

[fiffi]

Hab´ich bei stockworld gefunden:

Biogen hat "jede Menge Luft nach oben" (Briefing.com)

Die Analysten der US-amerikanischen Finanzseite Briefing.com erachten den Biotechnologie-Titel Biogen [Nasdaq:BGEN Kurs / Chart ] auf dem aktuellen Kursniveau als "attraktiv". Als Kursziel nannte der zuständige Experte 102 US-Dollar.

Biogen entwickelt, produziert und vermarktet Medikamente.

In seiner Begründung sagte der Analyst, dass der jüngste Kursrückschlag im Biotechnologie-Sektor – ebenso wie der starke Kursanstieg in den Wochen zuvor – eine Übertreibung seitens der Anleger darstelle. Seiner Ansicht nach sei der Titel zu Unrecht unter Druck gekommen, da Biogen eines der wenigen Unternehmen innerhalb der Branche sei, das bereits Gewinne vorweisen könne.

Für das laufende Fiskaljahr erwarte er einen Gewinn je Aktie von 1,81 US-Dollar, für 2001 einen von 2,12 US-Dollar. Die durchschnittliche Wachstumsrate über die kommenden fünf Jahre werde 24 Prozent betragen. Darüber hinaus verfüge Biogen mit 650 Millionen US-Dollar über volle Kassen und sei praktisch schuldenfrei.

Mit einem "fairen" Kurs-Gewinn-Verhältnis (KGV) von 48 auf Basis der nächstjährigen Gewinne ergebe sich für Biogen ein Kurspotenzial von derzeit 45 Prozent.


© 06.04.2000 www.stock-world.de


Viel Spaß noch mit "unserer Biogen"

fiffi

[local hero 3]

hallo spirou,

eines ist sicher, avonex "gehört" biogen. Warum allerdings ares-serono dafür lizenzeinnahmen erhält bleibt mir erst einmal ungewiss.

Folgenden Artikel habe ich gefunden, der klarstellt, dass REBIF (Ares-serono) ein Konkurrenzprodukt zu AVONEX ist und leider in der USA keine Zulassung erhalten hat.

Biogen
Biotech Navigator
Aug 27 1999
Overview

Biogen, Inc. is a biopharmaceutical company principally engaged in the business of developing, manufacturing and marketing drugs for human health care. The company focuses its efforts on areas where it has particular scientific strengths: multiple sclerosis, kidney diseases, inflammatory diseases, respiratory diseases, cardiovascular diseases, developmental biology and gene therapy.

Technology

Biogen`s research is focused on biological systems and processes where its scientific expertise in molecular biology, cell biology, immunology and protein chemistry can lead to a greater understanding of disease processes and, as a result, to the creation of new pharmaceuticals.

Valuation

With the prospect of Rebif (Ares-Serono) as a potential competitive threat in the US is eliminated and Rebif`s clinical data held in question by the FDA, Avonex will continue to dominate Multiple Sclerosis (MS) market. And more importantly, Rebif cannot be granted a marketing license in the U.S. until 2003, when the orphan drug status on Biogen`s Avonex expires. Avonex is currently the leading therapeutic for MS and has been protected by the orphan drug law since its approval in 1996. Biogen has secured a 60% market share in the MS market since Avonex` approval nearly three years ago. Schering/Chiron`s Betaseron was marketed earlier in 1993; however, Avonex circumvented Betaseron`s orphan drug status with its superior safety and efficacy profile and, since then, has held a strong cornerstone in the multiple sclerosis market. The FDA decision guarantees exclusivity to Biogen and Schering/Chiron for another four years, until 2003. The earliest time at which Rebif can receive marketing approval in the U.S. would be when this license expires.

In our opinion, with strong fundamentals and positive market sentiment, price momentum continues to remain favorable for Biogen, We expect strong growth in earnings and product sales, progress of pipeline products and potential upside on royalties to be catalysts for price appreciation. Even with the recent approval of the high dose for Rebif in Europe, we believe Biogen retains a marketing advantage.

All beta interferons are similar. Avonex (Biogen), Betaseron (Chiron/Schering AG), and Rebif (Ares-Serono) probably have similar efficacy in treating multiple sclerosis patients, but patients and physicians seem to prefer Avonex`s once a week intramuscular injection schedule as opposed to other more frequent (every other day) subcutaneous dosing. The multiple sclerosis market is growing through earlier diagnosis and treatment and will continue to grow as community-based neurologists begin to incorporate the latest research on beta-interferons into their practice.

[spirou]

Hallo zusammen,
ich warte noch auf eine Mail, um endlich die Sache mit den Linzenzgebühren
von Biogen für ares-serono zu klären.

schönen Tag noch

spirou

[Netrider]

Hallo Leute !

Biogen meldet heute nach Börsenschluss seine Quartalszahlen. Erwartet werden 0,43 cents je Aktie. Die Flüsterschätzung liegt bei 0,45 cents je Aktie. Ich hoffe, daß wir die 0,45 cents sehen, ansonsten könnte Biogen weiter unter Druck kommen. Dennoch könnten positive NEWS bei der Conf. Call um 5.00 pm kommen. Dies würde wir eine kurze Raelly bei Biogen sorgen. Lassen wir und überraschen...

MfG
Netrider

[spirou]

Hallo zusammen,
das tut weh. Leider fehlt der Einbruch auch noch stärker wegen dem Einbruch
der Nasdaq ein....nein....nein...nein

trotzdem schönen Abend noch (habe nachgekauft, da ich eine Gegenreaktion von rund 10 % erwarte)

spirou


UPDATE 1-Biogen profit comes short of forecast, stock off (Releads, adds details, stock action,
executive, analyst quotes, background, paragraphs 1,2,4,5,9-11, PVS CAMBRIDGE)

By Tony Munroe

BOSTON, Mass., April 10 (Reuters) - Biogen Inc. <BGEN.O>, the biotechnology company that makes the leading multiple
sclerosis drug, on Monday posted first-quarter earnings, excluding a one-time gain, that fell 2 cents short of forecasts, sending its
stock plunging in after-hours trade.

The Cambridge, Mass., biotech said profit reached 41 cents per diluted share, excluding a one-time gain of 36 cents, compared
with a consensus estimate of 43 cents, according to analysts surveyed by First Call/Thomson Financial.

Shares of Biogen, which makes Avonex, the most widely prescribed treatment for MS, fell to 62-3/4 in after-hours trading on
Island ECN, after dropping 2-1/16 to close at 65 on Nasdaq. The earnings were announced after the close of Nasdaq trading.

Biogen`s net income rose to $121.3 million, or 77 cents a share, including a gain of $90 million on securities sales, which added
36 cents to the bottom line. That compares with earnings of $45.6 million, or 29 cents, in the same quarter a year ago.

Biogen President and Chief Operating Officer James Mullen attributed Biogen`s lower-than-expected earnings to a slowdown in
growth of the overall market for drugs to treat MS -- a chronic, disabling disease of the central nervous system.

He also cited a decline in the company`s market share in Europe to about 36 percent from 38 percent a year ago, though its
U.S. share remained unchanged in the 55-60 percent range.

"There`s been a slowing of the overall market growth, and it`s been a very competitive market in Europe," he said in an interview.

Biogen revenues rose to $216.8 million from $171.7 million, while sales of Avonex climbed to $174.5 million from $131.3
million -- which fell short of at least one analyst`s estimate.

Biotechnology analyst Robert LeBoyer of Leerink Swann & Co. said before Biogen`s earnings release that he was looking for
Avonex sales in the range of $180 million to $185 million.

Biogen is essentially a one-drug company. Avonex competes with Schering AG`s <SCHG.F> Betaseron, and Copaxone, made
by Teva Pharmaceutical Industries Ltd. <TEVA.O> <TEVA.TA>.

The most promising drug in Biogen`s pipeline is psoriasis treatment Amevive, which is in Phase III trials and targeted for release
in 2002.

Some company-watchers have fretted that Biogen relies too heavily on Avonex. "As great as it is, they have one drug for
psoriasis coming after that, but not that much in the pipeline," LeBoyer said before the earnings release.

Mullen said he was comfortable with the First Call full-year earnings forecast range averaging $1.81 a share, and said the
company was on track to surpass 100,000 Avonex patients by year-end. Biogen said in its statement it had about 86,000
worldwide Avonex patients.

[maliany]

...jaja, bad news, wo immer man hinschaut... aber ich war wohl naiv, zu glauben, die wären schon im Preis inbegriffen. Als Biogen letzte Woche nicht auf 60 gefallen ist, habe ich sie gekauft, für 72 Euro, ich gebe es zu... und dann das... soll ich mich gleich erhängen oder warten, bis sie auf 72 DM steht????? Oder weiter in Medtronic investieren, weil die Herzschrittmacher produzieren??? Mehr als Sarkasmus fällt mir im Moment nicht ein. Vielleicht hilft Augen zubinden??? Oh Gott, Oh Gott,...

[maliany]

downgrade von ABN Anro, danke, danke, viiiiiielen dank

[AlexiusStrategist]

analysten downgraden gute stocks nur wenns ie billig einkaufen wollen.
denk mal darüber nach
in 4 bis 6 wochen stehen die wieder auf 75
mit respekt
http://www.amainvest.de

[Blue Boy]

Hi ihr Mitleidenden !!!

Könnt mich auch selbst windelweich schlagen !!!

Habe, als Biogen bei 62$ stand 30.000 Stck. von OS: 920072 gekauft. War eigentlich eher zum traden gedacht. Biogen ist darauf hin auch bis auf 75$ (intraday) gestiegen. WARUM hab ich Voll... nicht verkauft ?!? Ich dachte daß sie noch weiter steigen (Celera und Clinton), aber es ging von da an nur noch Berg ab ! Habe zur Zeit einen Buchverlust von ca. 70% !!! Wenn ich überleg, daß ich schon 100% im Plus war ist das um so schmerzlicher ! Naja, ich glaub das wird schon wieder !!! Hab soeben (bei 53$) nochmal 20.000 Stck. nachgekauft.

Gruß, Blue Boy

[maliany]

Kann bitte mal jemand den Titel dieses Threads ("Biogen verzeichnet rasanten Anstieg") ändern? Ich kriege immer feuchte Augen, wenn ich das lese...

[spirou]

hallo leute,
habe jetzt bei 55,50 Euro nachgekauft.......alles wird gut

spirou

[maliany]

lalala, always look on the bright side of life, lalala

Related Quotes

BGEN
53 33/64
-11 31/64

delayed 20 mins - disclaimer


Tuesday April 11, 12:47 pm Eastern Time
RESEARCH ALERT-Biogen is cut by PaineWebber, Prudential
NEW YORK, April 11 (Reuters) - PaineWebber and Prudential Securities on Tuesday cut their ratings on Biogen Inc. (NasdaqNM:BGEN - news) after the biotech company reported lower-than-expected first-quarter earnings amid a slowdown in sales growth of its drug Avonex for multiple sclerosis.

-- PaineWebber said analyst Elise Wang cut her rating on the Cambridge, Mass.-based drugmaker to attractive from buy.

-- Prudential said its biotech analyst Peter Drake lowered his rating to accumulate from strong buy.

-- Biogen late Monday posted first-quarter earnings, excluding a one-time gain, that fell 2 cents short of analysts` forecasts; its revenues rose to $216.8 million from $171.7 million, while sales of Avonex climbed to $174.5 million from $131.3 million.

-- PaineWebber`s Wang said she had expected Avonex sales of $180 million and said that ``sluggish Avonex sales and higher operating expenses generate a lower-than-expected earnings result.``

-- PaineWebber said Biogen management indicated the slowdown in Avonex U.S. sales "was driven by seasonal factors, a Y2K effect, and a reduction in the average inventory holding period by wholesalers.

-- ``We estimate this change in inventory practices may have accounted for approximately $5 million that we would have otherwise expected in additional Avonex sales.``

-- PaineWebber said Avonex faced ``increased competition in Europe and reduced pricing in certain key European countries, causing sales to be lower than expected.``

-- Prudential`s Drake said he was downgrading Biogen ``because we believe Avonex growth is slowing.``

-- said he believes the company is not properly addressing threats from rival drugs for multiple sclerosis.

-- Prudential lowered its 2000 sales estimate for Avonex to $787 million from $815 million.

-- Biogen shares were off 11 to 54 in heavy trade on the Nasdaq at midday.